The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia.

According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from ...

Moderna has withdrawn the Biologics License Application (BLA) for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after ...

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.

The approval in previously treated pediatric patients was based on data from the Alfa-PROTECT and PROTECT Kids studies.

Nature Made, CeraVe, and Neutrogena placed No. 1 in three or more categories for best OTC product. The companies with the most No. 1 products were Haleon (23), Kenvue Inc. (17), Prestige Consumer ...

HealthDay News — Drug overdose deaths decreased by 26.9% from 2023 to 2024, according to provisional data released today from the National Center for Health Statistics.

Brekiya consists of dihydroergotamine mesylate, an ergotamine derivative, in a single-dose autoinjector for subcutaneous administration.

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.